Overview

• Michelle Gidion was diagnosed with acute myeloid leukemia (AML) in May 2023 after a routine blood test revealed dangerously low platelet levels.
• Despite initial chemotherapy-induced remission and a subsequent stem cell transplant, she faced multiple relapses and diminishing treatment options by mid-2024.
• In July 2024, she enrolled in the international CAMELOT-1 trial for bleximenib, a menin inhibitor targeting leukemia cell survival mechanisms.
• As of April 2025, Gidion has achieved complete molecular remission with no detectable cancer, a milestone for the trial showing a 41% response rate so far.
• The trial continues to recruit globally, offering hope for AML patients with specific genetic mutations who have relapsed after standard treatments.